AFP and hepatocellular carcinoma: For non-antiviral group, the abnormal percentage of AFP levels were lower in patients with AST ≤ 1× ULN than in patients with AST > 1× ULN in the CHB, cirrhosis, and early-stage HCC subgroups (8.7% vs. 46.0%, p < 0.001; 15.6% vs. 58.2%, p < 0.001; and 58.1% vs. 76.1%, p < 0.001, respectively).